# Omada Health, Inc.: overview OMDA · Nasdaq · CIK 1611115 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/omda.md) · [Financials](/companies/omda/financials.md) · [Filings](/companies/omda/filings.md) · [Insiders](/companies/omda/insiders.md) Latest reported revenue: [$87.8m](/filings/0001628280-26-054840.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054840). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [45.5](/filings/0001628280-25-050622.md) | [48.0 d](/filings/0001628280-26-015637.md) | [55.0](/filings/0001628280-26-032875.md) | [61.4](/filings/0001628280-26-054840.md) | [68.0](/filings/0001628280-25-050622.md) | [75.8 d](/filings/0001628280-26-015637.md) | [78.0](/filings/0001628280-26-032875.md) | [87.8](/filings/0001628280-26-054840.md) | | Gross margin | % | [62.8%](/filings/0001628280-25-050622.md) | [67.0% d](/filings/0001628280-26-015637.md) | [58.0%](/filings/0001628280-26-032875.md) | [65.7%](/filings/0001628280-26-054840.md) | [66.3%](/filings/0001628280-25-050622.md) | [70.8% d](/filings/0001628280-26-015637.md) | [62.4%](/filings/0001628280-26-032875.md) | [72.6%](/filings/0001628280-26-054840.md) | | Operating margin | % | [(18.7%)](/filings/0001628280-25-050622.md) | [(14.8%) d](/filings/0001628280-26-015637.md) | [(15.3%)](/filings/0001628280-26-032875.md) | [(7.1%)](/filings/0001628280-26-054840.md) | [(3.7%)](/filings/0001628280-25-050622.md) | [4.3% d](/filings/0001628280-26-015637.md) | [(6.1%)](/filings/0001628280-26-032875.md) | [4.0%](/filings/0001628280-26-054840.md) | | Net margin | % | [(20.3%)](/filings/0001628280-25-050622.md) | [(17.2%) d](/filings/0001628280-26-015637.md) | [(17.2%)](/filings/0001628280-26-054840.md) | [(8.7%)](/filings/0001628280-26-054840.md) | [(4.7%)](/filings/0001628280-25-050622.md) | [6.8% d](/filings/0001628280-26-015637.md) | [(3.8%)](/filings/0001628280-26-054840.md) | [6.0%](/filings/0001628280-26-054840.md) | | Diluted EPS | $ per share | [(1.18)](/filings/0001628280-25-050622.md) | not reported | [(1.15)](/filings/0001628280-26-032875.md) | [(0.24)](/filings/0001628280-26-054840.md) | [(0.06)](/filings/0001628280-25-050622.md) | not reported | [(0.05)](/filings/0001628280-26-032875.md) | [0.08](/filings/0001628280-26-054840.md) | | Free cash flow | $m | [1.0 d](/filings/0001628280-25-050622.md) | [(6.7) d](/filings/0001628280-26-015637.md) | [(16.4)](/filings/0001628280-26-032875.md) | [2.6 d](/filings/0001628280-26-054840.md) | [9.6 d](/filings/0001628280-25-050622.md) | [21.2 d](/filings/0001628280-26-015637.md) | [(11.9)](/filings/0001628280-26-032875.md) | [3.9 d](/filings/0001628280-26-054840.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [123](/filings/0001628280-26-015637.md) | [170](/filings/0001628280-26-015637.md) | [260](/filings/0001628280-26-015637.md) | | Gross margin | % | [57.0%](/filings/0001628280-26-015637.md) | [60.6%](/filings/0001628280-26-015637.md) | [65.7%](/filings/0001628280-26-015637.md) | | Operating margin | % | [(53.8%)](/filings/0001628280-26-015637.md) | [(25.7%)](/filings/0001628280-26-015637.md) | [(4.6%)](/filings/0001628280-26-015637.md) | | Net margin | % | [(55.0%)](/filings/0001628280-26-015637.md) | [(27.8%)](/filings/0001628280-26-015637.md) | [(4.9%)](/filings/0001628280-26-015637.md) | | Diluted EPS | $ per share | [(9.52)](/filings/0001628280-26-015637.md) | [(6.11)](/filings/0001628280-26-015637.md) | [(0.35)](/filings/0001628280-26-015637.md) | | Free cash flow | $m | [(50.2)](/filings/0001628280-26-015637.md) | [(34.8)](/filings/0001628280-26-015637.md) | [16.9](/filings/0001628280-26-015637.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/omda/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Revelation Capital Management, LLC](/funds/1801811.md) | 2026-06-30 | $106.6m | 4,858,034 | | Reduced −350,000 | | [Divisadero Street Capital Management, LP](/funds/1901865.md) | 2026-06-30 | $83.4m | 3,799,695 | | Reduced −2,088,020 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $80.7m | 3,678,676 | | Added +1,222,367 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $61.5m | 2,800,887 | | Added +1,334,111 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $60.9m | 2,775,102 | | Reduced −513,278 | | [NVP ASSOCIATES, LLC](/funds/1545692.md) | 2026-06-30 | $55.6m | 2,531,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $48.8m | 2,222,074 | | Added +317,516 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $42.3m | 1,926,594 | | Added +117,610 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $37.8m | 1,724,057 | | Added +620,062 | | [LOOMIS SAYLES & CO L P](/funds/312348.md) | 2026-06-30 | $35.1m | 1,598,787 | | Reduced −113,989 | ## Recent filings [All 233 filings](/companies/omda/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-07 | 16:13 ET | [10-Q](/filings/0001628280-26-054840.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054840 | | 2026-08-06 | 16:02 ET | [8-K](/filings/0001628280-26-054266.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-054266 | | 2026-06-16 | 16:08 ET | [8-K](/filings/0001628280-26-043537.md) | 5.07 Shareholder vote results | 0001628280-26-043537 | | 2026-05-08 | 16:12 ET | [10-Q](/filings/0001628280-26-032875.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032875 | | 2026-05-07 | 16:01 ET | [8-K](/filings/0001628280-26-032063.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032063 | | 2026-04-28 | 16:10 ET | [DEF 14A](/filings/0001628280-26-027923.md) | Proxy statement, period 2026-06-16 | 0001628280-26-027923 | | 2026-03-06 | 16:32 ET | [10-K](/filings/0001628280-26-015637.md) | Annual report, period 2025-12-31 | 0001628280-26-015637 | | 2026-03-05 | 16:02 ET | [8-K](/filings/0001628280-26-015153.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-015153 | | 2026-01-12 | 09:06 ET | [8-K](/filings/0001628280-26-001781.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-001781 | | 2025-11-07 | 16:04 ET | [10-Q](/filings/0001628280-25-050622.md) | Quarterly report, period 2025-09-30 | 0001628280-25-050622 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-015637.md), filed Mar 6, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/54835948-5c0f-4e71-86ee-9b28c74a3628) ## About the filer - CIK: 1611115 - Tickers: OMDA - Exchange: Nasdaq - SIC code: 8000 Services-Health Services - State of incorporation: DE - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.